Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Heart Transplant Rejection - Overview
Heart Transplant Rejection - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Heart Transplant Rejection - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Heart Transplant Rejection - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Bristol-Myers Squibb Co
Kiniksa Pharmaceuticals Ltd
Nekol Sarl
Tonix Pharmaceuticals Holding Corp
Heart Transplant Rejection - Drug Profiles
AS-2521780 - Drug Profile
Product Description
Mechanism Of Action
AS-2553627 - Drug Profile
Product Description
Mechanism Of Action
Autologous thyTreg - Drug Profile
Product Description
Mechanism Of Action
belatacept - Drug Profile
Product Description
Mechanism Of Action
KPL-404 - Drug Profile
Product Description
Mechanism Of Action
Monoclol Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation - Drug Profile
Product Description
Mechanism Of Action
TNX-1500 - Drug Profile
Product Description
Mechanism Of Action
tofacitinib - Drug Profile
Product Description
Mechanism Of Action
Heart Transplant Rejection - Dormant Projects
Heart Transplant Rejection - Product Development Milestones
Featured News & Press Releases
May 31, 2022: Tonix Pharmaceuticals announces two oral presentations involving TNX-1500 (Fc-modified anti-CD40L mAb) on prevention of rejection in kidney and heart allograft transplantation at the 2022 American Transplant Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Heart Transplant Rejection, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Heart Transplant Rejection, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Heart Transplant Rejection - Pipeline by Astellas Pharma Inc, 2022
Heart Transplant Rejection - Pipeline by Bristol-Myers Squibb Co, 2022
Heart Transplant Rejection - Pipeline by Kiniksa Pharmaceuticals Ltd, 2022
Heart Transplant Rejection - Pipeline by Nekonal Sarl, 2022
Heart Transplant Rejection - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
Heart Transplant Rejection - Dormant Projects, 2022